Low expression of MN1 associates with better treatment response in older patients with de novo cytogenetically normal acute myeloid leukemia

TET2Mutations Improve the New European LeukemiaNet Risk Classification of Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2011) Klaus H. Metzeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutations of the Wilms tumor 1 gene (WT1) in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) H. Becker et al.   BLOOD

FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) S. P. Whitman et al.   BLOOD

BAALC and ERG expression levels are associated with outcome and distinct gene and microRNA expression profiles in older patients with de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

(2010) S. Schwind et al.   BLOOD

Prognostic Significance of Expression of a Single MicroRNA,miR-181a, in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Sebastian Schwind et al.   JOURNAL OF CLINICAL ONCOLOGY

IDH1andIDH2Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2010) Guido Marcucci et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Modeling the functional heterogeneity of leukemia stem cells: role of STAT5 in leukemia stem cell self-renewal

(2009) M. Heuser et al.   BLOOD

Clinical implications of molecular genetic aberrations in acute myeloid leukemia

(2009) Sebastian Scholl et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Prognostic Importance ofMN1Transcript Levels, and Biologic Insights FromMN1-Associated Gene and MicroRNA Expression Signatures in Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study

(2009) Christian Langer et al.   JOURNAL OF CLINICAL ONCOLOGY

ERGExpression Is an Independent Prognostic Factor and Allows Refined Risk Stratification in Cytogenetically Normal Acute Myeloid Leukemia: A Comprehensive Analysis ofERG, MN1, andBAALCTranscript Levels Using Oligonucleotide Microarrays

(2009) Klaus H. Metzeler et al.   JOURNAL OF CLINICAL ONCOLOGY

Favorable Prognostic Impact ofNPM1Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study

(2009) Heiko Becker et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of miR-145 and miR-146a as mediators of the 5q– syndrome phenotype

(2009) Daniel T Starczynowski et al.   NATURE MEDICINE

miR-449a targets HDAC-1 and induces growth arrest in prostate cancer

(2009) E J Noonan et al.   ONCOGENE

Amplification and Overexpression of Hsa-miR-30b, Hsa-miR-30d and KHDRBS3 at 8q24.22-q24.23 in Medulloblastoma

(2009) Yuan Lu et al.   PLoS One

High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study

(2008) C. Langer et al.   BLOOD

Distinctive Patterns of MicroRNA Expression Associated with Karyotype in Acute Myeloid Leukaemia

(2008) Amanda Dixon-McIver et al.   PLoS One

Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2

(2008) C. Katz et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA